Chitguppi Chandala, Koszewski Ian, Collura Kaitlin, Curtis Mark, Nyquist Gurston, Rabinowitz Mindy, Rosen Marc
Division of Rhinology and Endoscopic Skull Base Surgery, Department of Otolaryngology - Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States.
J Neurol Surg B Skull Base. 2019 Feb;80(1):51-58. doi: 10.1055/s-0038-1667146. Epub 2018 Jul 16.
Biphenotypic sinonasal sarcoma is a recently described malignancy showing dual differentiation with both myogenic and neural elements. Due to its histologic similarities to other sinonasal malignancies, it is a diagnostic challenge. The main purpose of this article is to report a case of biphenotypic sinonasal sarcoma and to consolidate data and provide a comprehensive review regarding pathological differences between biphenotypic sarcoma and other sinonasal malignancies and diagnostic modalities used for biphenotypic sarcoma. A systematic review of all cases of biphenotypic sinonasal sarcoma was performed using electronic databases (PubMed and Medline). Data collected included age, gender, symptoms, sub-site of origin, immunophenotyping, metastasis, recurrence, treatment, duration of follow-up, and survival outcomes. Ninety-five cases of biphenotypic sarcoma were found with mean age at diagnosis of 52.36 years (range, 24-87 years). Female to male ratio was 2.27:1. Extra-sinonasal extension was present in 28%. Immunophenotyping revealed that S-100 and SMA (smooth muscle actin) were consistently positive, while SOX-10 was consistently negative. PAX3-MAML3 fusion [t (2; 4) (q35; q31.1)] was the most common genetic rearrangement. Surgical excision with or without adjuvant radiotherapy was the most frequent treatment modality used. Recurrence was observed in 32% of cases with follow-up. None of the cases reported metastasis. Three patients had died at the time of publication that included one case with intracranial extension. Biphenotypic sarcoma is distinct sinonasal malignancy with unique clinicopathological features. Testing involving a battery of myogenic and neural immunomarkers is essential for diagnostic confirmation and is a clinically useful endeavor when clinical suspicion is high.
双表型鼻窦肉瘤是一种最近才被描述的恶性肿瘤,表现出肌源性和神经成分的双重分化。由于其组织学特征与其他鼻窦恶性肿瘤相似,因此在诊断上具有挑战性。 本文的主要目的是报告一例双表型鼻窦肉瘤病例,整合数据,并对双表型肉瘤与其他鼻窦恶性肿瘤之间的病理差异以及用于双表型肉瘤的诊断方法进行全面综述。 使用电子数据库(PubMed和Medline)对所有双表型鼻窦肉瘤病例进行了系统综述。收集的数据包括年龄、性别、症状、起源亚部位、免疫表型分析、转移、复发、治疗、随访时间和生存结果。 共发现95例双表型肉瘤,诊断时的平均年龄为52.36岁(范围为24 - 87岁)。女性与男性的比例为2.27:1。28%的病例存在鼻窦外扩展。免疫表型分析显示,S - 100和SMA(平滑肌肌动蛋白)始终呈阳性,而SOX - 10始终呈阴性。PAX3 - MAML3融合[t(2;4)(q35;q31.1)]是最常见的基因重排。最常用的治疗方式是手术切除加或不加辅助放疗。随访中32%的病例出现复发。所有病例均未报告有转移。在发表时,有3例患者死亡,其中1例有颅内扩展。 双表型肉瘤是一种具有独特临床病理特征的鼻窦恶性肿瘤。涉及一系列肌源性和神经免疫标志物的检测对于确诊至关重要,当临床怀疑度较高时,这是一项具有临床实用价值且需要努力去做的工作。